Abbott Laboratories (NYSE:ABT) will release its first-quarter earnings results before the opening bell on Wednesday, April 16.

Analysts expect the company to report quarterly earnings at $1.07 per share, up from 98 cents per share in the year-ago period. According to data from Benzinga Pro, Abbott Laboratories projects quarterly revenue at $10.41 billion, compared to $9.96 billion a year earlier.

On March 10, Bank of America Securities analyst Travis Steed maintained Abbott with a Buy rating and raised the price target from $133 to $150.

With the recent buzz around Abbott Laboratories, some investors may be eyeing potential gains from the company’s dividends. Currently, Abbott offers an annual dividend yield of 1.84%. That’s a quarterly dividend amount of 59 cents per share ($2.36 …

Full story available on Benzinga.com

Abbott Laboratories (NYSE:ABT) will release its first-quarter earnings results before the opening bell on Wednesday, April 16.

Analysts expect the company to report quarterly earnings at $1.07 per share, up from 98 cents per share in the year-ago period. According to data from Benzinga Pro, Abbott Laboratories projects quarterly revenue at $10.41 billion, compared to $9.96 billion a year earlier.

On March 10, Bank of America Securities analyst Travis Steed maintained Abbott with a Buy rating and raised the price target from $133 to $150.

With the recent buzz around Abbott Laboratories, some investors may be eyeing potential gains from the company’s dividends. Currently, Abbott offers an annual dividend yield of 1.84%. That’s a quarterly dividend amount of 59 cents per share ($2.36 …

Full story available on Benzinga.com

 Abbott Laboratories (NYSE:ABT) will release its first-quarter earnings results before the opening bell on Wednesday, April 16.
Analysts expect the company to report quarterly earnings at $1.07 per share, up from 98 cents per share in the year-ago period. According to data from Benzinga Pro, Abbott Laboratories projects quarterly revenue at $10.41 billion, compared to $9.96 billion a year earlier.
On March 10, Bank of America Securities analyst Travis Steed maintained Abbott with a Buy rating and raised the price target from $133 to $150.
With the recent buzz around Abbott Laboratories, some investors may be eyeing potential gains from the company’s dividends. Currently, Abbott offers an annual dividend yield of 1.84%. That’s a quarterly dividend amount of 59 cents per share ($2.36 …Full story available on Benzinga.com   Read MoreABT, Biotech, Earnings, Long Ideas, News, pharmaceuticals, Stories That Matter, Markets, Trading Ideas, ABT, US0028241000, Long Ideas, News, Earnings, Markets, Trading Ideas, Benzinga Markets